HomeBUSINESS
BUSINESS

AZ to Transfer Migraine Med Zomig to Sawai Mid-Next Year
(Oct.6.2017)

The Japan arm of AstraZeneca will transfer its off-patent migraine treatment Zomig (zolmitriptan) to Japanese generic major Sawai Pharmaceutical, with the transaction expected to be completed around mid-next year, the two companies said on October 4 ...
(LOG IN FOR FULL STORY)

News Calendar